High HNRNPA3 expression is associated with lymph node metastasis and poor prognosis in patients treated with radical cystectomy

Amano, Noriyuki; Matsumoto, Kazumasa; Shimizu, Yuriko; Nakamura, Marie; Tsumura, Hideyasu; Ishii, Daisuke; Sato, Yuichi

doi:10.1016/j.urolonc.2020.10.072

Cited by 5 publications

(4 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Three-micron-thick sections were immunostained using the BOND-MAX automated immunohistochemistry system and Bond Polymer Refine Detection kit DS 9800 (Leica Biosystems, Newcastle, UK), following our previous studies with minor modifications [ 32 ]; tissues obtained by RC were deparaffinized and pretreated with Bond Epitope Retrieval Solution 2 (Leica Biosystems) at 100 °C for 20 min. After washing and peroxidase blocking for 10 min, tissues were re-washed, and immunohistochemistry was performed for AHNAK2 on the specimens by rabbit polyclonal anti-AHNAK2 antibody (HPA004145; Sigma-Aldrich, St. Louis, MO, USA, diluted 1:1000).…”

Section: Methodsmentioning

confidence: 99%

Prognostic Impact of AHNAK2 Expression in Patients Treated with Radical Cystectomy

Koguchi

Matsumoto

Shimizu

et al. 2021

Cancers

Self Cite

View full text Add to dashboard Cite

Data regarding expression levels of AHNAK2 in bladder cancer (BCa) have been very scarce. We retrospectively reviewed clinical data including clinicopathological features in 120 patients who underwent radical cystectomy (RC) for BCa. The expression levels of AHNAK2 in the specimens obtained by RC were classified as low expression (LE) or high expression (HE) by immunohistochemical staining. Statistical analyses were performed to compare associations between the two AHNAK2 expression patterns and the prognoses in terms of recurrence-free survival (RFS) and cancer-specific survival (CSS). A Kaplan–Meier analysis showed that patients with HE had a significantly worse RFS and CSS than those with LE (hazard ratio [HR]: 1.78, 95% confidence interval [CI]: 1.02–2.98, p = 0.027 and HR: 1.91, 95% CI: 1.08–3.38, p = 0.023, respectively). In a multivariate analysis, independent risk factors for worse RFS and CSS were shown as HE (HR: 1.96, 95% CI: 1.08–3.53, p = 0.026 and HR: 2.22, 95% CI: 1.14–4.31, p = 0.019, respectively) and lymph node metastasis (HR: 2.04, 95% CI: 1.09–3.84, p = 0.026 and HR: 1.19, 95% CI: 1.25–4.97, p = 0.009, respectively). The present study showed that AHNAK2 acts as a novel prognostic biomarker in patients with RC for BCa.

show abstract

Section: Methodsmentioning

confidence: 99%

Prognostic Impact of AHNAK2 Expression in Patients Treated with Radical Cystectomy

Koguchi

Matsumoto

Shimizu

et al. 2021

Cancers

Self Cite

View full text Add to dashboard Cite

show abstract

“…A recent study by Amano et al, on the heterogeneous nuclear ribonucleoprotein A3 (HNRNPA3) expression, was shown to be significantly associated with lymph node metastasis and S100A8, S100A9, and uroplakin III expressions (Amano et al 2021 ).…”

Section: Proteomic Biomarkersmentioning

confidence: 99%

Current look at the most promising proteomic and glycomic biomarkers of bladder cancer

Harsanyi,

Kianickova,

Katrlik

et al. 2024

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Background Bladder cancer (BC) belongs to the most frequent cancer types. The diagnostic process is still long and costly, with a high percentage of false-positive or -negative results. Due to the cost and lack of effectiveness, older methods need to be supplemented or replaced by a newer more reliable method. In this regard, proteins and glycoproteins pose high potential. Methods We performed an online search in PubMed/Medline, Scopus, and Web of Science databases to find relevant studies published in English up until May 2023. If applicable, we set the AUC threshold to 0.90 and sensitivity/specificity (SN/SP) to 90%. Findings Protein and glycoprotein biomarkers are a demonstrably viable option in BC diagnostics. Cholinesterase shows promise in progression-free survival. BLCA-4, ORM-1 along with HTRA1 in the detection of BC. Matrix metallopeptidase 9 exhibits potential for stratification of muscle-invasive subtypes with high negative predictive value for aggressive phenotypes. Distinguishing non-muscle invasive subtypes benefits from Keratin 17. Neu5Gc-modified UMOD glycoproteins pose potential in BC diagnosis, while fibronectin, laminin-5, collagen type IV, and lamprey immunity protein in early detection of BC.

show abstract

“…Therefore, hnRNPA3 was proposed as a valuable differential diagnostic and prognostic biomarker during the multistep process of HCC carcinogenesis [ 133 ]. Furthermore, hnRNPA3 exhibited potential as a marker for advanced CRC in proteomics [ 134 ] and showed a high correlation with lymph node metastasis and poor prognosis in BCa patients undergoing radical cystectomy in a retrospective clinical study [ 135 ]. Simultaneously, hnRNPA3 was a key candidate protein related to BCa cisplatin resistance [ 136 ] and glioblastoma TMZ resistance [ 137 ], and was even a crucial regulator improving the efficacy of irinotecan enhanced by the traditional Chinese herbal preparation PHY906 [ 138 ].…”

Section: The Roles Of Hnrnpa/b In Cancers: Molecular Mechanisms and C...mentioning

confidence: 99%

Heterogeneous nuclear ribonucleoprotein A/B: an emerging group of cancer biomarkers and therapeutic targets

Wang

et al. 2022

Cell Death Discov.

View full text Add to dashboard Cite

Heterogeneous nuclear ribonucleoprotein A/B (hnRNPA/B) is one of the core members of the RNA binding protein (RBP) hnRNPs family, including four main subtypes, A0, A1, A2/B1 and A3, which share the similar structure and functions. With the advance in understanding the molecular biology of hnRNPA/B, it has been gradually revealed that hnRNPA/B plays a critical role in almost the entire steps of RNA life cycle and its aberrant expression and mutation have important effects on the occurrence and progression of various cancers. This review focuses on the clinical significance of hnRNPA/B in various cancers and systematically summarizes its biological function and molecular mechanisms.

show abstract

High HNRNPA3 expression is associated with lymph node metastasis and poor prognosis in patients treated with radical cystectomy

Cited by 5 publications

References 32 publications

Prognostic Impact of AHNAK2 Expression in Patients Treated with Radical Cystectomy

Prognostic Impact of AHNAK2 Expression in Patients Treated with Radical Cystectomy

Current look at the most promising proteomic and glycomic biomarkers of bladder cancer

Heterogeneous nuclear ribonucleoprotein A/B: an emerging group of cancer biomarkers and therapeutic targets

Contact Info

Product

Resources

About